Cargando…

A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Young implantable cardioverter-defibrillator (ICD) recipients present high rate of inappropriate shocks and complications. Some of them seem to be underestimated. The subcutaneous ICD(S-ICD) system was developed to eliminate lead-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewandowski, M, Syska, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207371/
http://dx.doi.org/10.1093/europace/euad122.424
_version_ 1785046439124008960
author Lewandowski, M
Syska, P
author_facet Lewandowski, M
Syska, P
author_sort Lewandowski, M
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Young implantable cardioverter-defibrillator (ICD) recipients present high rate of inappropriate shocks and complications. Some of them seem to be underestimated. The subcutaneous ICD(S-ICD) system was developed to eliminate lead-related complications and was proved to be effective, avoiding intracardiac and endovascular adhesions. Aims To report on our clinical experience with transvenous (TV-ICD) and S-ICD therapy in patients under thirty years of age. METHODS: We reviewed database of ICD recipients in our institution between 1996 and 2022(25 years) and have chosen 125 pts consecutively implanted up to and including the age of 30 years. We retrospectively analyzed the rate of appropriate(AI) and inappropriate interventions(IS), lead complications rate, infection rate, mortality and treatment options. RESULTS: The study group: 84 TV-ICD(age: 6-30, BMI: 16,3-22,2) and 41 S-ICD( age: 15-30, BMI; 15,6-31,1) patients. The mean follow-up in analyzed groups was 159±48 and 40± 2 months respectively. Abnormal ventricular function: EF≤30 occurred in compared groups: 12/84(14%) and 5/41(12%) respectively, p=0,3. 24/84pts(28%) received ≥1 AI for VT/VF(ATP or shock) in TV-ICD and 4/40pts(10%) in S-ICD groups. 25/84 pts(30%) received one or multiple (IS) and 1/40pts(2,5%) in compared groups respectively, p=0,02. There were 18/84 (21.5%) ventricular lead dysfunctions(reimplantation of a new system) in TV-ICD and 0% in S-ICD groups, p=0,025. An infection rate (endocarditis or device pocket )was 8/84 (10%) in TV-ICD group with complete system removal and 1 pts (2,5%) wound infection(staphylococcus aureus) in S-ICD group successfully treated with antibiotics. 1 left ventricular assist device was implanted in end-stage heart failure S-ICD patient with good result. There were 2 S-ICD implantations as a concomitant device i.e. conversion of TV-ICD(with therapy OFF) to S-ICD due to ventricular lead dysfunction. 4(10%) pts required generator elective replacement due to early battery depletion in S-ICD group. In 2(5%)pts right sternal lead location was chosen due to better sensing results. Mortality rate was 6/84 pts (7%), caused by ventricular lead dysfunction, end-stage heart failure or heart transplantation fatal result in TV-ICD group. There was no death in S-ICD group. CONCLUSIONS: TV- ICD implantation in children and young adults is a feasible and effective procedure in a 25-year follow-up but the rate of complications is high in this population. S-ICD recipients did not experienced lead failures or systematic infections. S-ICD appears to be a good therapy option and an alternative to TV-ICD in pediatric and young patients population, preventing from some serious lead complications and tricuspid valve regurgitation. The method and follow-up period effect is present between the TV-ICD and S-ICD in analyzed groups. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10207371
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102073712023-05-25 A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age Lewandowski, M Syska, P Europace 14.2 - Implantable Cardioverter-Defibrillator (ICD) FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Young implantable cardioverter-defibrillator (ICD) recipients present high rate of inappropriate shocks and complications. Some of them seem to be underestimated. The subcutaneous ICD(S-ICD) system was developed to eliminate lead-related complications and was proved to be effective, avoiding intracardiac and endovascular adhesions. Aims To report on our clinical experience with transvenous (TV-ICD) and S-ICD therapy in patients under thirty years of age. METHODS: We reviewed database of ICD recipients in our institution between 1996 and 2022(25 years) and have chosen 125 pts consecutively implanted up to and including the age of 30 years. We retrospectively analyzed the rate of appropriate(AI) and inappropriate interventions(IS), lead complications rate, infection rate, mortality and treatment options. RESULTS: The study group: 84 TV-ICD(age: 6-30, BMI: 16,3-22,2) and 41 S-ICD( age: 15-30, BMI; 15,6-31,1) patients. The mean follow-up in analyzed groups was 159±48 and 40± 2 months respectively. Abnormal ventricular function: EF≤30 occurred in compared groups: 12/84(14%) and 5/41(12%) respectively, p=0,3. 24/84pts(28%) received ≥1 AI for VT/VF(ATP or shock) in TV-ICD and 4/40pts(10%) in S-ICD groups. 25/84 pts(30%) received one or multiple (IS) and 1/40pts(2,5%) in compared groups respectively, p=0,02. There were 18/84 (21.5%) ventricular lead dysfunctions(reimplantation of a new system) in TV-ICD and 0% in S-ICD groups, p=0,025. An infection rate (endocarditis or device pocket )was 8/84 (10%) in TV-ICD group with complete system removal and 1 pts (2,5%) wound infection(staphylococcus aureus) in S-ICD group successfully treated with antibiotics. 1 left ventricular assist device was implanted in end-stage heart failure S-ICD patient with good result. There were 2 S-ICD implantations as a concomitant device i.e. conversion of TV-ICD(with therapy OFF) to S-ICD due to ventricular lead dysfunction. 4(10%) pts required generator elective replacement due to early battery depletion in S-ICD group. In 2(5%)pts right sternal lead location was chosen due to better sensing results. Mortality rate was 6/84 pts (7%), caused by ventricular lead dysfunction, end-stage heart failure or heart transplantation fatal result in TV-ICD group. There was no death in S-ICD group. CONCLUSIONS: TV- ICD implantation in children and young adults is a feasible and effective procedure in a 25-year follow-up but the rate of complications is high in this population. S-ICD recipients did not experienced lead failures or systematic infections. S-ICD appears to be a good therapy option and an alternative to TV-ICD in pediatric and young patients population, preventing from some serious lead complications and tricuspid valve regurgitation. The method and follow-up period effect is present between the TV-ICD and S-ICD in analyzed groups. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207371/ http://dx.doi.org/10.1093/europace/euad122.424 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 14.2 - Implantable Cardioverter-Defibrillator (ICD)
Lewandowski, M
Syska, P
A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age
title A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age
title_full A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age
title_fullStr A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age
title_full_unstemmed A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age
title_short A 25-year single-center experience with transvenous and subcutaneous ICD patients under thirty years of age
title_sort 25-year single-center experience with transvenous and subcutaneous icd patients under thirty years of age
topic 14.2 - Implantable Cardioverter-Defibrillator (ICD)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207371/
http://dx.doi.org/10.1093/europace/euad122.424
work_keys_str_mv AT lewandowskim a25yearsinglecenterexperiencewithtransvenousandsubcutaneousicdpatientsunderthirtyyearsofage
AT syskap a25yearsinglecenterexperiencewithtransvenousandsubcutaneousicdpatientsunderthirtyyearsofage
AT lewandowskim 25yearsinglecenterexperiencewithtransvenousandsubcutaneousicdpatientsunderthirtyyearsofage
AT syskap 25yearsinglecenterexperiencewithtransvenousandsubcutaneousicdpatientsunderthirtyyearsofage